Predictive Biomarker Sciences (PBS-Bio) in Mesa, Arizona said today that it signed new contracts with three companies developing therapies against a variety of cancers. PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.
The company’s three new pharmaceutical partners include:
- ENDECE, in Mequon, Wisconsin that discovers and develops anti-cancer compounds, including their lead compound NDC-1308, which target molecular “bioswitches” that control metabolic pathways impacting cancer cell growth.
- Revalesio Corporation in Tacoma, Washington, that develops therapeutic candidates containing “charged-stabilized nanostructures” to prevent inflammatory mediated diseases without inhibiting normal cellular functions.
- Unibioscreen, in Brussels, Belgium, that is developing UNBS1450, an anti-cancer drug now in European clinical trials.
PBS-Bio says its technology analyzes primary tumor cell lines’ responses to investigational drugs through the use of several types of fluorescent reporters observed over a time-course. The results offer a better understanding of molecular mechanisms for drug susceptibility and resistance. The findings also also can lead to further experiments using combinatorial regimens as well as better identification of patients most likely to respond to the investigational drugs.
You must be logged in to post a comment.